Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252615 · ClinicalTrials.gov registry record · Phase 2
Patient and Partner Intervention After an Implantable Cardioverter Defibrillator (ICD)
A Phase 2 study of Implantable Cardioverter Defibrillator (ICD), sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 1
- Study location
NCT01252615: Completed Phase 2 study of Implantable Cardioverter Defibrillator (ICD), sponsored by University of Washington.
NCT01252615 is a Phase 2 study of Implantable Cardioverter Defibrillator (ICD) that has completed, run by University of Washington. The registered enrollment target is 301 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01252615, a Phase 2 study of Implantable Cardioverter Defibrillator (ICD), has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to compare a patient only to a patient+partner intervention on recovery outcomes of patients and partners after Implantable Cardioverter Defibrillator (ICD) implantation.
Primary Outcome
symptoms, health related quality of life, steps/day
Conditions Studied
Interventions
- BEHAVIORAL patient only
- BEHAVIORAL patient and partner intervention
Study Locations (1)
Washington
- Cynthia M. Dougherty - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT01252615 record still lists
NCT01252615 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 1 condition, with Implantable Cardioverter Defibrillator (ICD) appearing as the primary indexed condition, and to 2 interventions - of which patient only is the first listed.
NCT01252615 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01252615 about?
NCT01252615 is a clinical study titled "Patient and Partner Intervention After an Implantable Cardioverter Defibrillator (ICD)". The goal of this study is to compare a patient only to a patient+partner intervention on recovery outcomes of patients and partners after Implantable Cardioverter Defibrillator (ICD) implantation.
What is the current status of trial NCT01252615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2009-07. Estimated completion is 2015-10.
What conditions does trial NCT01252615 study?
This clinical trial studies the following conditions: Implantable Cardioverter Defibrillator (ICD).
What interventions are being tested in trial NCT01252615?
The interventions under investigation include: patient only (BEHAVIORAL), patient and partner intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01252615?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01252615 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Implantable Cardioverter Defibrillator (ICD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01252615's enrollment target sits among peer trials
301 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia